Advances in the treatment of gastrointestinal stromal tumours

Miettinen, 2001, Gastrointestinal stromal tumors—definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis, Virchows Arch, 438, 1, 10.1007/s004280000338 Nilsson, 2005, Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era—a population-based study in western Sweden, Cancer, 103, 821, 10.1002/cncr.20862 Joensuu, 2004, Gastrointestinal stromal tumors—a review, Acta Orthop Scand, 75, 62, 10.1080/00016470410001708340 Judson, 2002, Gastrointestinal stromal tumours (GIST): biology and treatment, Ann Oncol, 13, 287, 10.1093/annonc/mdf672 Dematteo, 2000, Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival, Ann Surg, 231, 51, 10.1097/00000658-200001000-00008 Hirota, 1998, Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors, Science, 279, 577, 10.1126/science.279.5350.577 Rubin, 2001, KIT activation is a ubiquitous feature of gastrointestinal stromal tumors, Cancer Res, 61, 8118 D’Amato, 2005, Update on the biology and therapy of gastrointestinal stromal tumors, Cancer Control, 12, 44, 10.1177/107327480501200106 Heinrich, 2003, PDGFRA activating mutations in gastrointestinal stromal tumors, Science, 299, 5708, 10.1126/science.1079666 Heinrich, 2003, Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor, J Clin Oncol, 21, 4342, 10.1200/JCO.2003.04.190 Demetri, 2002, Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors, N Engl J Med, 347, 472, 10.1056/NEJMoa020461 Rankin, 2004, Dose effect of imatinib (IM) in patients (pts) with metastatic GIST - phase III sarcoma group study S0033, J Clin Oncol, 22, 10.1200/jco.2004.22.14_suppl.9005 Verweij, 2004, Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial, Lancet, 364, 1127, 10.1016/S0140-6736(04)17098-0 Zalcberg, 2005, Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800mg after progression on 400mg, Eur J Cancer, 41, 1751, 10.1016/j.ejca.2005.04.034 Glabbeke, 2005, J Clin Oncol, 23, 5795, 10.1200/JCO.2005.11.601 Debiec-Rychter, 2006, KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours, Eur J Cancer, 42, 1093, 10.1016/j.ejca.2006.01.030 Heinrich, 2006, Molecular correlates of imatinib resistance in gastrointestinal stromal tumors Abrams, 2003, SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer, Mol Cancer Ther, 2, 471 Kim, 2006, An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases, J Clin Endocrinol Metab, 91, 4070, 10.1210/jc.2005-2845 Mendel, 2003, In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship, Clin Cancer Res, 9, 327 Murray, 2003, SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model, Clin Exp Metastasis, 20, 757, 10.1023/B:CLIN.0000006873.65590.68 O’Farrell, 2003, SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo, Blood, 101, 3597, 10.1182/blood-2002-07-2307 Osusky, 2004, The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels, Angiogenesis, 7, 225, 10.1007/s10456-004-3149-y Schueneman, 2003, SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models, Cancer Res, 63, 4009 Heinrich, 2006, Sunitinib (SU) response in imatinib-resistant (IM-R) GIST correlates with KIT and PDGFRA mutation status Morgan, 2006, Durable responses to SU11248 (sunitinib malate) are observed across all genotypes of imatinib mesylateresistant GIST Demetri, 2006, Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial, Lancet, 368, 1329, 10.1016/S0140-6736(06)69446-4 Judson, 2006, Updated results from a phase III trial of sunitinib in advanced gastrointestinal stromal tumuor (GIST), Ann Oncol, 17, 162 Casali, 2006, Updated results from a phase III trial of sunitinib in GIST patients (pts) for whom imatinib (IM) therapy has failed due to resistance or intolerance Dileo, 2006, Updated results from a ‘‘treatment-use’’ trial of sunitinib in advanced gastrointestinal stromal tumor (GIST) Blay, 2006, Clinical benefit of continuous daily dosing of sunitinib in patients (pts) with advanced gastrointestinal stromal tumor (GIST)